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ABSTRACT 
 
Aims: To investigate the effect of methotrexate and soy isoflavones genistein and daidzein on 
MDA-MB-231 breast cancer cell viability.  
Study Design: In-vitro study using cultured cells 
Place and Duration of Study: Nutrition Innovations Centre for Food & Health (NICHE), School of 
Biomedical Sciences, Ulster University, data collected September 2014-2015. 
Methods: Human breast cancer MDA-MB-231 cells were cultured in DMEM (with 10% FBS, 1% 
Pen strep) and treated with methotrexate, genistein or daidzein for 72 hrs. Combinations treatments 
used non-fixed ratios of methotrexate (0-100 µM) and genistein or daidzein (30 µM) with cell 
viability monitored using the MTT assay.   
Results: The 50% effect dose (EC50) was 44.7±6.4 µM for methotrexate, 55.8±3.9 µM for 
genistein or 67.4±12.2 µM for daidzein. Combination treatments with genistein or daidzein 
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produced EC50 of 57.6±2.0 or 29.7±2.4 µM for methotrexate, respectively. The combination index 
(CI) was 1.9 for methotrexate-genistein whilst CI was 1.1 for methotrexate-daidzein near the 
median dose. Values for CI decreased from 5.0 towards 1.0 as the ratio of methotrexate: isoflavone 
increased. The results are discussed in terms of prevailing ideas concerning how phytochemicals 
affects drug adsorption, distribution, metabolism and excretion (ADME) and the expected 
consequences for cytotoxicity. 
Conclusions: Treatment of MDA-MB-231 breast cancer cells with methotrexate and genistein or 
daidzein produces interactions consistent with antagonism (CI =1.1-5.0) but the effects are 
predicted to diminish with rising methotrexate to isoflavone ratio. 
 
 
Keywords: Methotrexate; breast cancer; isoflavones; genistein; daidzein; interactions. 
 
1. INTRODUCTION  
 
Methotrexate is used frequently for treating 
leukemia, solid tumors and rheumatoid arthritis 
[1]. Acquired resistance to methotrexate [2] 
prompts high-dose therapy leading to a likelihood 
of toxic side-effects [3]. Combination therapy with 
antioxidant phytochemicals was proposed to 
mitigate the toxic side effects associated             
with methotrexate but the impact on drug 
effectiveness remains controversial [4,5,6]. 
Observational studies showed there were low 
rates of breast cancer incidence in Asian women 
linked to the consumption of soy products [7]. A 
variety of soybean products were found to 
prevent methotrexate gastro-intestinal toxicity, 
but the anti-apoptotic components appeared to 
be relatively high molecular weight (>10 kd) 
compounds [8]. Soy isoflavones possess 
anticancer activity [9,10]. Genistein produces 
synergisms with other anticancer agents due to a 
chemo-sensitizing effect [10,11].  
 
To our knowledge no investigation of the effect of 
soy isoflavones on methotrexate cytotoxicity 
towards breast cancer cells has been published. 
The aim of this study was to investigate the effect 
of methotrexate combined with soy isoflavones 
genistein and daidzein on MDA-MB-231 breast 
cancer cell viability. The approach conforms to a 
variable ratio method for assessing interactions 
using the median effect model detailed by Chou 
and co-workers [12]. 
 
2. MATERIALS AND METHODS  
 
Methotrexate, genistein, daidzein, 3-(4,5-
dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT), dimethyl Sulfoxide (DMSO) and 
other chemicals were obtained from Sigma-
Aldrich (UK).Human breast cancer cell line MDA-
MB-231 was from American Type Cell           
Culture Collection (LGC Standards Teddington, 
Middlesex, UK). Dulbecco's Modified Eagle's 
Medium (DMEM) type 31885 (with low glucose), 
Fetal bovine serum (FBS), Trypsin (1X) and 
consumables for cell culture were from Fischer 
Scientific- Invitrogen Ltd (UK). 
 
2.1 Cell Culture 
 
MDA-MB-231 breast cancer cells were cultured 
using DMEM medium supplemented with +10% 
FBS and 1% pen step. Culture flasks and 96-well 
micro-plates were incubated at 37°C in a 5% 
CO2 atmosphere (LEEC Research CO2 
Incubator, LEEC Ltd., Nottingham, UK).  Cells 
were trypsinized, counted using a NucleoCounter 
(model NC-3000, ChemoMetec, Allerod, 
Denmark) and seeded at 10,000 cells/well in 96 
well plates with 50 µl media per well. Cells were 
incubated overnight at 37°C to allow attachment.  
 
Stock solutions of methotrexate, genistein, and 
daidzein (100 mM) were prepared with DMSO, 
diluted 10 fold with DMEM and sterilized with 0.2 
µm cellulose acetate filters before use. Sterilized 
solutions were serially diluted to achieve 2x 
target concentration (max; 200 µM with <0.05% 
DMSO final concentration). Cells were treated 
with methotrexate, genistein or daidzein alone 
and incubated for 72 hours. Cell viability was 
determined using the MTT assay (Section 2.2.). 
These tests were analyzed to find EC50 values 
and such data were used for the design of 
combination studies.  
 
2.2 MTT Assay 
 
Microwell plates were washed x 2-fold with ice 
cold PBS (100 µl) with a third wash remaining in 
the wells. MTT reagent 20 µl (5 mg/ ml in PBS 
buffer) was added per well and plates were 
incubated at 37°C for 2 hours. Blue formazan 
crystals formed were dissolved by adding 100 µl 
isopropanol (with 0.04N HCl) and incubating for 
one hour. Absorbances were measured at 570 
nm using a microplate reader (VersaMax™ 
ELISA microplate reader, Molecular Devices, 
Sunnyvale, CA, USA.).Data were expressed as 
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mean ± standard error of means (SEM) of 2-
independent experiments with six-replicate 
(microwells) per treatment-concentration (n=12).   
 
2.3 Combination Studies 
 
Samples containing (4x target concentration) 
methotrexate (25 µl) were added to microplate 
wells containing 10,000 seeded cells and 50 µl of 
culture media. Then 25 µl of genistein or 
daidzein (4x target concentrations) were added 
to achieve a final concentration equal to one-half 
of EC50 for each isoflavone. The final range of 
methotrexate concentrations were 0, 1, 2, 5, 10, 
20 and 100 µM.  The cells were incubated for 72 
hours and subjected to MTT assay as describe 
above. Combination test involved 3-independent 
experiments with 6 microwells per each 
treatment concentration (n=18). 
 
2.4 Data and Statistical Analysis 
 
Experimentally values for cell viability were fitted 
by non-linear regression (NLR) to the Logistics 
function shown below, where PRED is the 
predicted response, C = minimum response, and 
M= maximum response. E is 50% effect dose or 
drug-dose, which produces a 50% response 
(E50), and B is the steepness of the curve [13]. 
 
PRED =C+ ((M-C)/(1+EXP(B*Ln(D/E)))) 
 
NLR was implemented using SPSS software 
(IBM SPSS v21.). Estimates for EC50 were 
subjected to isobologram analysis. Dose-
response data were also analyzed median effect 
model. The fraction of affected cells (Fa) and 
unaffected cells (Fu) are calculated for different 
doses of drug (Fa = 100-% viable cells/100 and 
Fu = 1-Fa). A plot of log (Fa/Fu) versus drug 
concentration was fitted to a straight-line graph 
(Y = mx +c) to determine the median effect dose 
(Dm) and slope (m) using CompuSyn™ software 
[12]. Values for the combination Index (CI) were 
calculated either manually or via CompuSyn™. 
To determine CI manually, we used the            
relations below, where d50MTX and d50Gen are 
the 50% effect dose from combination studies, 
and EC501 and EC502 are values for each agent 
alone. 
 
  	
	

501
	

502
		 
  
The size of CI is indication whether combination 
therapies produce synergism (CI<1.0), 
antagonism (CI>1.0) or additive behavior 
(CI=1.0) [13]. 
3. RESULTS  
 
3.1 Dose-response Parameters  
 
Table 1 and Fig. 1 show dose-effect parameters 
for MDA-MB-231 cells treated with methotrexate, 
genistein or daidzein determined using a logistic 
function to fit experimental data. There was a 
good fit for NLR predictions with observed points 
(R2 = 0.98-0.99). Table 2 shows dose-effect 
parameters arising from CompuSyn™ analysis of 
the same data. The median dose (Dm) 
corresponds to the 50% effect dose (EC50) and 
slope (m) is a measures of the steepness of the 
plot of log (Fa/Fu) versus drug concentration. 
 
 
 
 
 
 
 
Fig. 1. Dose response curve for MDA-MB-231 
breast cancer cells treated with methotrexate, 
genistein or daidzein as single treatments 
Continuous lines shows response predicted by NLR. 
Experimental points are shown as means ± SD (n=12) 
from two independent experiments 
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Table 1. Dose-response parameters for MDA-MB-231 breast cancer cells treated using 
methotrexate and isoflavones determined by non-linear regression analysis (SPSS) 
 
Agent/ NLR parameter EC50 (E)µM Slope (B) Max (M) 
Methotrexate 44.7±6.4 1.14±0.29 96.2±3.3 
Genistein 55.8±3.9 1.17±0.11 97.4±1.7 
Daidzein 67.4±12.2 2.1±2.20 102.0±1.0 
Methotrexate (+30µM Genistein) 57.6+2.0 0.62±0.04 99.0±0.54 
Methotrexate (+30µM Daidzein) 29.7±2.4 0.40±0.02 111±2.0 
Data shows mean ±SEM as determined by NLR with bootstrap; Parameters are EC50 (E), response slope (B) 
and maximum cell viability (Max). The lower-limit for cell viability (C) was constrained as zero during NLR 
 
Table 2. Dose-response parameters for MDA-MB-231 breast cancer cell treated with 
methotrexate, genistein or daidzein as determined by CompuSyn * 
 
Agent/parameter Dm (µM) Slope (m) r 
Methotrexate 42.1±5.0 0.46±0.08 0.916±0.005 
Genistein 50.4±2.6 0.88±0.31 0.996±0.064 
Daidzein 64.1±1.5 1.90±0.18 0.911±0.005 
*Mean ±SD, from two independent experiments with 6 replicates per drug dose, n=12. Dm = median dose (µM), 
m = response slope, r = regression coefficient 
 
Results for NLR analysis of treatments 
combining methotrexate and genistein or 
daidzein are shown in Fig. 2. Isobologram 
analysis predicted EC50 values for methotrexate 
of 20-22 µM in the presence 30 µM daidzein 
(~1/2 EC50 dose). The actual EC50 values 
observed by for methotrexate combinations with 
genistein or daidzein are shown Table 1. 
 
         
 
Fig. 2. Combination treatment of MDA-MB-231 breast cancer cells using methotrexate and 
isoflavones 
Notes (left panel) methotrexate plus genistein (MTXGEN), (Right-panel) methotrexate plus daidzein (MTXDAIDZ) 
 
         
Fig. 3. Isobologram for methotrexate combination with daidzein or genistein 
The iso-effective doses predicted to produce 50% effect when daidzein (DAIDZ) or genistein (GEN) is added with 
methotrexate (MTX) in a variety of doses; () = observed EC50 for combination studies. Dotted = predicted in 
this study for additive (no interaction) response between two agents 
Maginnes
The combination index (CI) value using data from 
Table 1 was CI = 1.9 for methotrexate
and CI = 1.1 for methotrexate
combination at the concentrations corresponding 
to 50% effect. The values for CI were predicted 
to increase from 1.1 to 5.0 (Fig. 4) with 
decreasing methotrexate: isoflavone ratio 
(Fig.  4).  
 
 
Fig. 4. A plot of combination index (CI) values 
for treatment of MDA-MB-231 breast cancer 
cells with methotrexate (1-100 µM) and 30
daidzein or genistein
Data generated using CompuSyn analysis
 
4. DISCUSSION 
 
Methotrexate is an anticancer agent [1
Consumption of soy isoflavones is thought to 
reduce the risk of breast cancer [8,9,
Methotrexate inhibits cell proliferation by blocking 
the enzyme dihydrofolate reductase (DHFR), 
depleting the intracellular pool of fo
restriction of methyl-group availability for DNA 
synthesis [1]. In addition, exposure to 
methotrexate increases intracellular oxidative 
stress due to the inhibition of NAD(P)H
reductases [14,15]. Soy isoflavones show 
estrogen receptor activation, tyrosine kinase 
inhibition, induction of cell-cycle arrest, anti
inflammatory action, and general antioxidant 
activity [10,16,17]. For the preceding reasons, we 
tested the hypothesis that combination of 
methotrexate with isoflavones would produce
enhanced anti-cancer activity compared with 
each agent alone.   
 
EC50 values from this study (Table 1) are in 
broad agreement with previous reports, taking 
account of differences in assay conditions, e.g. 
different culture medium, and drug exposure 
times. The EC50 was 80 µM for methotrexate 
treatment of MDA-MB-231 cultured with MEM 
media and a drug exposure time of 24
By comparison, EC50 was 18.5 µM methotrexate 
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-genistein 
-daidzein 
         
 
-µM 
 
 
-3,14]. 
10]. 
late, and by 
-liked 
-
 
 hrs [18]. 
with low protein (5% FBS) medium [19]. Tests 
using genistein and MDA-MB-231 cells sho
that EC50 ranges from 46.8 µM [20] to 50
[21,22] depending on the exposure time and 
other assay conditions.  
 
There was antagonism between methotrexate 
and soy isoflavones in this study. The EC50 for 
methotrexate increased from 44.7 µM to 57.6 µM 
in the presence of genistein with CI>1.0 
indicating antagonism. The EC50 value for 
methotrexate with daidzein present (29.7 µM) 
was closer to values (20-22 µM) predicted by 
isobologram analysis (Fig. 3) for additive 
response meaning  neither positive nor negative 
interaction (Table 1 and Fig. 3.) but here also CI 
>1.0. For both isoflavones CI> 1.0 indicating 
antagonism. The degree antagonism between 
methotrexate and genistein seem to be greater 
than those with daidzein. Co
predictions showed decreasing antagonism 
(Fig. 4) with increasing methotrexate: isoflavones 
ratio. 
 
Relating in-vitro data to human exposure 
conditions requires that EC50s are subjected to 
in-vitro, in vivo extrapolation (IVIVE) by step
correction for the effects of absorption, serum 
protein binding, liver metabolism and renal 
clearance [23,24]. Past literature, data may be 
useful also for addressing IVIVE issues. Briefly, it 
is known that methotrexate is bioavailable
oral doses of < 20 mg/m2 (<0.54
methotrexate are 50-95% absorbed leading to 
peak plasma concentrations of 300
within 1.5-3 hours and a half-life of elimination of 
4-6h [3]. Most of the circulating methotrexate is 
excreted via the kidneys in an intact form with 
<10% metabolism in the liver to form 7
methotrexate [3]. On the other hand, the plasma
concentration profile for soy isoflavones is 
influenced by a host of factors, e.g. relative 
proportion of aglycone and glycosylated forms, 
type of food matrix used for administration, and 
forms of processing [25]. Using the dose for 
genistein or daidzein frequently used in human 
trials (45-56 mg/ day), the fractional excretion 
rate (apparent bioavailability) was 20
peak plasma concentration of 2-5 µM some 4
8hrs after intake [26]; reviewed by [
basis of such data [3,26,27], a typical exposure 
to 20 mg methotrexate + 56mg genistein would 
produce plasma concentrations for methotrexate 
that are 60-400 times higher compared to 
peak plasma concentration for isoflavone. 
Moreover, the peak concentrations for isoflavone 
would occur after the peak for methotrexate 
[3,26,27]. According to the present paper high 
 
 
.35206 
 
 
wed 
-90 µM 
mpuSynTm 
           
wise 
 and 
 mg/Kg) 
-2000 µM 
-OH 
-
-50% with a 
-
27]. On the 
the 
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methotrexate: isoflavone ratios are not conducive 
for antagonism. 
 
Evidence is emerging that antioxidant 
phytochemicals can reduce toxicity to healthy 
cells, whilst not affecting efficacy [4-7] depending 
on changes to absorption, metabolism, 
distribution and excretion (ADME) characteristics 
[15,28,29,30]. Research using leukemic cells 
showed that genistein inhibits methotrexate 
uptake by the reduced folate transporter owing to 
its role as tyrosine kinase inhibitor [31,32,33]. 
Genistein was found to promote the transcription 
of efflux transporter (ABCC1/MRP1) protein               
for MDA-MB-231 cells with no net effect 
onmitoxantrone toxicity owing to the 
simultaneous inhibition of the same transporter 
[34]. Many polyphenols from beverages were 
also reported to inhibit methotrexate and folate 
uptake at low pH involving the proton coupled 
folate transporter [35-39]; genistein had no effect 
on the low-pH uptake of methotrexate and folate 
by CaCo2 cells [35].  Interestingly, genistein was 
reported to moderate genes from MDA-MB-231 
cells suppressed by epigenetic mechanism [21] 
thereby increasing the cell sensitivity to 
therapeutic drugs. In general, methotrexate 
toxicity would be enhanced by phytochemicals 
that increase uptake, promote methotrexate 
modification to polyglutamated forms, and / or 
decrease methotrexate efflux [15]. For example, 
genistein (and its metabolites) were found to be 
inhibitors for breast cancer resistant protein 
(ABCG2/BCRP) efflux transporter [40,41]. 
Methotrexate and 7-OH methotrexate were also 
identified as substrates for ABCC2 (MRP2), 
ABCC3 (MRP3), and ABCG2/BCRP) and found 
to have an enormous impact on drug 
concentration profile [29].  
 
5. CONCLUSION 
 
In conclusion, a diverse range of potential 
interactions may occur between genistein and 
methotrexate that go to produce antagonism with 
regard to cytoxicity for MDA-MB-231 cells. The 
results from this study show a rising tolerance of 
breast cancer cells towards methotrexate in the 
presence of genistein. However, we speculate 
that antagonism is unlikely where concentrations 
for methotrexate are much higher than               
genistein. More research is needed also to 
consider methotrexate interactions with 
isoflavones in terms of changes to ADME and 
the consequences for other health outcomes. 
The different levels of antagonism observed                  
for methotrexate and genistein or daidzein is 
interesting and worthy of further study.           
There is scope also to consider the possible              
role of soy isoflavone/ MTX therapy on             
immune responses or rheumatoid arthritis 
[1,3,8,14,35,36]. 
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